OBJECTIVE:To observe the clinical efficacy of Tanreqing injection in the treatment of children's viral pneumonia.METHODS:A total of sixty children with viral pneumonia were randomly divided into 2 groups:the treatment group(n=30)were treated with Tanreqing injection(20mL)plus Glucose(250mL)qd for 7d while the control group(n=30)with Cibavirin(10～15mg?kg-1)plus Glucose(250mL)bid for 7d.The primary outcome measures were clinical efficacy and adverse drug effects(ADRs).RESULTS:The effective rate was 100% in the treatment group as compared with 80% in the control group,showing significant differences between the two groups(P

0.05),the incidence of adverse drug reactions were 3.5% and 2.4%,respectively and the total treatment costs were(4 146.45?282.15)yuan and(4 807.20?318.15)yuan,respectively;and the cost-minimization analysis showed that manicol was the preferred therapy as compared with Glycerol Fructose.In the treatment of the patients with cerebral infarction complicating renal dysfunction,the total effective rates of the two drugs were 80.0% and 93.3%,respectively(P

OBJECTIVE:To evaluate the cost-effectiveness of Tanreqing injection in treating children's viral pneumonia.METHODS:In this retrospective study,sixty children with viral pneumonia were randomly assigned to receive Tanreqing Injection(treatment Group,n=30)or Ribavirin(control Group,n=30).The clinical effects and adverse drug reactions(ADRs)of the two groups were compared,and the cost-effectiveness analyses were performed.RESULTS:The effective rate was 100% in the treatment Group versus 80% in the control Group;the incidence rate of ADRs was 3.33% vs.13.33%;the cost was 297.88 vs.399.95 yuan;and the cost-effectiveness was 297.88 vs.499.94,all showing significant differences between the two groups(P